ABSTRACT
Resumo Para se compreender a fundação, em 1900, e os primeiros trabalhos científicos do Instituto Soroterápico Federal, é necessário analisar a circulação de conhecimento e a disputa internacional envolvendo os soros antipestosos e as vacinas antipestosas. O artigo discute a criação do primeiro soro antipestoso, em Paris, e os testes realizados a partir de 1897 na Índia. Paralelamente, examina a invenção da vacina antipestosa na mesma época em Bombaim e a oposição construída entre ela e o soro antipestoso francês. Em seguida, observa os diferentes caminhos pelos quais esses objetos chegaram ao Brasil e como questões locais se conectaram à disputa científica internacional e justificaram, no Rio de Janeiro, reconfigurações em torno desses dois objetos.
Abstract In order to understand the 1900 establishment of the Federal Serum Therapy Institute of Manguinhos and its earliest scientific work, we must analyze the circulation of knowledge and international disputes surrounding antiplague serums and vaccines. This article discusses the development of the first antiplague serum, in Paris, and the trials conducted in India, which started in 1897. It also examines the invention of an antiplague vaccine in Bombay around the same time and the ensuing controversy involving it and the French serum. The article then explores the pathways by which these objects reached Brazil and also looks at how local issues there meshed with the international scientific dispute, ultimately justifying reconfigurations of the two objects in Rio de Janeiro.
Subject(s)
Humans , History, 19th Century , History, 20th Century , Plague/history , Plague Vaccine/history , Laboratories/history , Plague/prevention & control , Brazil , Serum , IndiaABSTRACT
ABSTRACT Objectives: The plague, which is an infectious disease caused by Yersinia pestis, still threatens many populations in several countries. The worldwide increase in human plague cases and the potential use of the bacteria as a biological weapon reinforce the need to study the immunity that is induced by potential vaccine candidates. To determine the immunogenicity of antigenic preparations based on the F1 protein and the total extract from Y. pestis, we assessed the role of these antigens in inducing an immune response. Methods: The immunogenicity of antigenic preparations based on the Y. pestis (YP) total extract and the Y. pestis fraction 1 capsular antigen protein (F1) was determined in Swiss-Webster mice immunized with 40 µg or 20 µg for each preparation. Immunophenotyping was performed by flow cytometry. Results: Animals immunized with the YP total extract did not elicit detectable anti-F1 antibodies (Ab) in the hemaglutination/inhibition (HA/HI) test. Animals immunized with 40 µg or 20 µg of the F1 protein produced anti-F1 Abs, with titres ranging from 1/16 to 1/8132. The average of CD3+-CD4+ and CD3+-CD8+ T cells did not differ significantly between the groups. Neither YP total extract nor F1 protein induced a significant expression of IFN-γ and IL-10 in CD4+ T lymphocytes. In addition, F1 failed to induce IFN-γ expression in CD8+ T cells, unlike the YP total extract. Conclusion: The results showed that F1 protein is not an immunogenic T cell antigen, although the YP total extract (40 µg dose) favoured CD8+ T cell-mediated cellular immunity.
Subject(s)
Animals , Female , Rats , Spleen/immunology , Yersinia pestis/immunology , Plague Vaccine/immunology , Immunogenicity, Vaccine , Antigens, Bacterial/immunology , Plague/prevention & control , Spleen/cytology , CD4-Positive T-Lymphocytes/immunology , Immunophenotyping , Interferon-gamma/immunology , Interleukin-10/immunology , CD4-CD8 Ratio , CD8-Positive T-Lymphocytes , Flow Cytometry , Immunity, CellularABSTRACT
Recombinant Fl-V (rFl-V) fusion protein is the main ingredient of the current candidate vaccine against Yersinia pestis infection, which has been under investigation in clinical trial in USA. We investigated the soluble expression conditions of rF1-V in Escherichia coli BL21 (DE3) that we constructed before. After scale-up and optimization of fermentation processes, we got the optimized fermentation process parameters: the culture was induced at the middle exponential phase with 50 µmol/L of IPTG at 25 °C for 5 h. Soluble rFl-V protein was isolated to 99% purity by ammonium sulfate precipitation, ion exchange chromatography, hydrophobic chromatography and gel filter chromatography. The protein recovery was above 20%. Protein identity and primary structure were verified by mass spectrometry and Edman sequencing. Results of purity, quality and western blotting analysis indicated that the target protein is a consistent and properly folded product. Furthermore, the immunogenicity of various antigens formulated with aluminum hydroxide adjuvant was evaluated in mice. Serum antibody titers of 4 groups including 20 µg rFl, rV and rFl-V and 10 µg rFl+10 µg rV, were assayed by ELISA after 2 doses. The antibody titers of anti-Fl with 20 µg rFl-V were obviously higher than titers with other groups; meanwhile there were no significant difference of anti-V antibody titers among them. These findings confirm that rFl-V would be the active pharmaceutical ingredient of the plague subunit vaccine.
Subject(s)
Animals , Mice , Adjuvants, Immunologic , Antibodies, Bacterial , Blood , Antibody Formation , Antigens, Bacterial , Allergy and Immunology , Blotting, Western , Chromatography, Ion Exchange , Enzyme-Linked Immunosorbent Assay , Plague , Plague Vaccine , Allergy and Immunology , Recombinant Fusion Proteins , Allergy and Immunology , Vaccines, Subunit , Allergy and Immunology , Yersinia pestisABSTRACT
<p><b>OBJECTIVE</b>LcrV is an important component for the development of a subunit vaccine against plague. To reduce immunosuppressive activity of LcrV, a recombinant LcrV variant lacking amino acids 271 to 326 (rV270) was prepared by different methods in this study.</p><p><b>METHODS</b>A new strategy that produced non-tagged or authentic rV270 protein was designed by insertion of rV270-thrombin-hexahistidine fusion gene into the vector pET24a, or by insertion of hexahistidine-enterokinase-rV270 or hexahistitine-factor Xa-rV270 fusion gene into the vector pET32a. After Co(2+) affinity chromatography, a purification strategy was developed by cleavage of His tag on column, following Sephacryl S-200HR column filtration chromatography.</p><p><b>RESULTS</b>Removal of His tag by thrombin, enterokinase and factor Xa displayed a yield of 99.5%, 32.4% and 15.3%, respectively. Following Sephacryl S-200HR column filtration chromatography, above 97% purity of rV270 protein was obtained. Purified rV270 that was adsorbed to 25% (v/v) Al(OH)₃ adjuvant in phosphate-buffered saline (PBS) induced very high titers of antibody to rV270 in BALB/c mice and protected them (100% survival) against subcutaneous challenge with 10⁶ CFU of Y. pestis virulent strain 141.</p><p><b>CONCLUSION</b>The completely authentic rV270 protein can be prepared by using enterokinase or factor Xa, but they exhibited extremely low cleavage activity to the corresponding recognition site. Thrombin cleavage is an efficient strategy to prepare non-tagged rV270 protein and can be easily operated in a large scale due to its relatively low cost and high cleavage efficacy. The recombinant rV270 can be used as a key component to develop a subunit vaccine of plague.</p>
Subject(s)
Animals , Female , Mice , Amino Acid Sequence , Antibodies, Bacterial , Blood , Antigens, Bacterial , Genetics , Allergy and Immunology , Blotting, Western , Cloning, Molecular , Electrophoresis, Polyacrylamide Gel , Escherichia coli , Genetics , Genetic Vectors , Mice, Inbred BALB C , Molecular Sequence Data , Plague , Allergy and Immunology , Plague Vaccine , Genetics , Allergy and Immunology , Plasmids , Pore Forming Cytotoxic Proteins , Genetics , Allergy and Immunology , Protein Engineering , Methods , Recombinant Fusion Proteins , Genetics , Allergy and Immunology , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Survival Analysis , Vaccines, Subunit , Genetics , Allergy and Immunology , Yersinia pestis , Allergy and ImmunologyABSTRACT
<p><b>OBJECTIVE</b>To evaluate the protective efficacy of plague subunit vaccine, BALB/c mice, guinea pigs and rabbits were used in this study.</p><p><b>METHODS</b>Groups of mice (10 per group), guinea pigs (14 per group) and rabbits (6 per group) were immunized with F1 + rV270 vaccine, EV76 vaccine and alum adjuvant by intramuscular route, respectively. Serum antibody titres of mice, guinea pigs and rabbits were determined by ELISA and the immunized animals were challenged with 10(6) CFU of Y. pestis strain 141 at the 8th week after the primary immunization.</p><p><b>RESULTS</b>The immunized mice, guinea pigs or rabbits with subunit vaccine developed anti-F1 IgG titre of 41 587.3 +/- 2.1, 11 543.7 +/- 2.1 or 522.4 +/- 22.4 and elicited statistical anti-F1 IgG titre difference among them (F = 17.58, P < 0.01). The immunized mice, guinea pigs or rabbits with subunit vaccine had anti-rV270 IgG titre of 15 748.7 +/- 1.6, 12.6 +/- 1.4 or 1648.0 +/- 5.0 and induced statistical anti-rV270 IgG titre difference among them (F value was 16.34, P < 0.01). There was significant anti-F1 IgG titre difference among mice, guinea pigs and rabbits immunized with EV76 vaccine that developed anti-F1 IgG titre of 913.4 +/- 4.5, 937.0 +/- 2.0 or 342.0 +/- 12.0 (F = 23.67, P < 0.01), whereas the immunized mice, guinea pigs and rabbits with EV76 vaccine developed anti-rV270 IgG titre of 12.0 +/- 1.0, 447.0 +/- 10.0, 40.0 +/- 11.0 and there was no anti-rV270 IgG titre difference between them (F = 2.20, P = 0.1314). The immunized mice with subunit vaccine developed significantly higher anti-F1 IgG titres than immunized guinea pigs and rabbits (q value was 30.57 and 19.04, respectively, P < 0.01), and there were no anti-F1 IgG titre differences between the immunized guinea pigs and rabbits (q = 0.04, P = 0.8485). The immunized mice with subunit vaccine developed significantly higher anti-rV270 IgG titres than immunized guinea pigs and rabbits (q value was 27.10 and 19.49, respectively, P < 0.01), and there were no anti-rV270 IgG titre differences between the immunized guinea pigs and rabbits with the subunit vaccine (q = 0.25, P = 0.6187). The immunized mice with EV76 elicited higher anti-F1 IgG titres than immunized guinea pigs and rabbits (q value was 40.67 and 29.10, respectively, P < 0.01), whereas there was no difference of F1 IgG titer between immunized guinea pigs and rabbits (q = 0.06, P = 0.8098). The immunized mice, guinea pigs and rabbits with subunit vaccine provided 100% (10/10), 86% (12/14) and 100% (5/5) protection against 10(6) CFU Y. pestis of challenge, respectively. The immunized mice, guinea pigs and rabbits with EV76 vaccine gave 100% (6/6), 93% (13/14) and 100% (6/6) protection against 10(6) CFU Y. pestis of challenge respectively.</p><p><b>CONCLUSION</b>BALB/c mice is the best small animal model for valuation of protective efficacy of plague subunit vaccine. The guinea pigs showed a high individual variation for this purpose. The rabbits can be used as an alternative model for evaluating plague subunit vaccine.</p>
Subject(s)
Animals , Female , Mice , Rabbits , Antibodies, Bacterial , Blood , Dose-Response Relationship, Immunologic , Guinea Pigs , Immunization , Immunoglobulin G , Blood , Mice, Inbred BALB C , Models, Animal , Plague , Plague Vaccine , Allergy and Immunology , Vaccines, Subunit , Allergy and ImmunologySubject(s)
Siphonaptera , Rats , Rodent Control , Plague/prevention & control , Plague Vaccine , Serologic Tests/methods , Immunization/methodsABSTRACT
La peste es una enfermedad infecciosa de tipo zoonótico que ha representado uno de los más serios problemas de salud pública en todo el mundo y debido a sus características pandémicas, mas que epidémicas, fue uno de los azotes de la antigüedad. Su agente etiológico es Yersinia pestis y la forma clínica más frecuente es una linfadentitis febril aguda o peste bubónica, aunque también se presentan formas septicémicas, neumónicas y meníngeas. En ausencia de tratamiento es sumamente mortal, pero esta se reduce notablemente si se instala una antibióticoterapia oportuna. La primera vacuna contra la peste fue elaborada por Haffkine en 1897 utilizando bacterias muertas; durante la Segunda Guerra Mundial y años después, en el ejército de los Estados Unidos se usó otro tipo de vacuna muerta con formalina y mediante sucesivas mejoras en los métodos de su producción se obtuvo, a partir de la cepa muy virulenta India 195/P de Y. pestis, la denominada vacuna contra la peste USP, medio E, ahora en uso; que se aplica en una primera serie de tres dosis intramusculares, la primera de 1 mL, seguida cuatro semanas más tarde de otra de 0.2 mL y 15 meses después de otros 0.2 mL. La efectividad de una serie primaria de vacunación nunca se ha medido en forma precisa; la experiencia en el campo indica que reduce la incidencia y severidad de la enfermedad posterior al piquete de pulgas infectadas. Se desconoce la protección que confiere contra la peste neumónica. Ya que la vacuna sólo aminora la sintomatología, se recomienda la administración profiláctica de antibióticos en todos los individuos que hayan estado expuestos al contagio, tengan o no antecedentes vacunales